Moderna (MRNA) has announced that the FDA has completed its review of the company’s Investigational New Drug (IND) application for its novel coronavirus vaccine candidate (mRNA-1273).The FDA will now allow the vaccine to proceed to a Phase 2 study, which is expected to begin shortly, Moderna revealed. Shares are surging 15% in Thursday’s pre-market trading, with the stock already recording a whopping 150% year-to-date gain.Looking further ahead, the company is also finalizing the protocol for the Phase 3 study of mRNA-1273, which is expected to begin in early summer of 2020.“The imminent Phase 2 study start is a crucial step …read more
Source:: Yahoo Finance
